Task Group Charge

To identify factors contributing to variation in access to and delivery of recommended lung nodule management, staging, and receipt of curative-intent surgery and radiation/SBRT for early-stage NSCLC, access to and use of  comphrehensive biomarker testing for targeted therapies, and strategies to overcome the factors contributing to this variation.


Gerard Silvestri headshot

Gerard A. Silvestri, MD, MS

Task Group Chair
Steering Committee Member
Medical University of South Carolina

Dr. Douglas Wood SCCA - photo by Kris Krüg

Douglas E. Wood, MD

Task Group Vice Chair
Vice Chair of NLCRT
University of Washington


Farhood Farjah, MD, MPH

Task Group Vice Chair
University of Washington

Task Group Members

Upal Basu Roy, PhD, MPH
LUNGevity Foundation

Vickie Beckler, MBA, RN

Leigh Boehmer, PharmD, BCOP
Association of Community Cancer Centers

Thomas D’Amico, MD
Duke Cancer Institute

Megan Daly, MD
UC Davis Comprehensive Cancer Center

Elizabeth David, MD, MAS
University of Southern California

Frank Detterbeck, MD
Yale Cancer Center

Stacey Fedewa, PhD
American Cancer Society

Jordan Garst
ALK Positive Outreach

Michael Gould, MD, MS
Kaiser Permanente

Louise M. Henderson, PhD, MSPH
University of North Carolina at Chapel Hill

James Jett, MD
National Jewish Health

Ella Kazerooni, MD, MS*
University of Michigan

Edward Kim, MD
Levine Cancer Institute

Jennifer King, PhD
GO2  Foundation for Lung Cancer

Christopher Lathan, MD, MS, MPH
Dana-Farber Medical Institute at St. Elizabeth’s Medical Center

Linda Martin, MD, MPH
University of Virginia

Nikki Martin, MA
LUNGevity Foundation

Renato Martins, MD, MPH
University of Washington

Rhonda Meckstroth
ALK Positive

Amy Moore, PhD
GOFoundation for Lung Cancer

Benjamin Movsas, MD
Henry Ford Health System

Gregory Riely, MD, PhD
Memorial Sloan Kettering Cancer Center

M. Patricia Rivera, MD
University of North Carolina at Chapel Hill

Albert Rizzo, MD
American Lung Association

Liora Sahar, PhD, GISP
American Cancer Society

Helmneh Sineshaw, MD, MPH
American Cancer Society

Robert Suh, MD
University of California, Los Angeles

William Travis, MD
Memorial Sloan Kettering Cancer Center

(*) indicates Steering Committee member

Opportunities For Intervention/Influence:

  • Address the lack of experience and/or expertise in screen-detected lung nodule management
  • Identify strategies to reduce the variation (geographic, SES, income, race/ethnicity, rural, etc.) in access to lung cancer specialists
  • Identify strategies to overcome the non-adherence with staging and management guidelines
  • Highlight the disparities in receipt of curative-intent surgery for early stage NSCLC and develop strategies to eliminate these disparities
  • Develop strategies to reduce the variability in access and use of comprehensive biomarker testing for expression of immune-markers and targeted therapy